Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Adds Cara Therapeutics Inc. (CARA) To Its Equity Portfolio

James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported a position in Cara Therapeutics Inc. (NASDAQ:CARA). The fund holds 350,000 shares of the Cara Therapeutics Inc. (NASDAQ:CARA), the stake amassing 1.55% of the common stock.

Cara Therapeutics

On Feb. 5, Cara Therapeutics Inc. (NASDAQ:CARA) announced the closing of its initial public offering of 5,750,000 shares of common stock at $11.00 per share. The offering included the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments.

Including the sale of the additional shares from the option, the net proceeds to the company from the initial public offering were about $55.9 million, after deducting underwriting discounts and commissions and estimated offering expenses, according to a news release.

Cara Therapeutics Inc. (NASDAQ:CARA) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. The company possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics.

Recently, Deerfield reported adding KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) to its equity portfolio. The fund currently holds around 3.18 million shares of the company, the passive stake amassing 9.64% of the common stock.

On Feb. Deerfield revealed holding shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX). The fund reported ownership of around 1.29 million class E preferred shares. The securities can be converted into shares of common stock on the basis of 0.222 shares of common stock per one unit of preferred stock.

As of September 30, 2013, Deerfield owned around 5.0 million shares of NxStage Medical Inc. (NASDAQ:NXTM), with a reported value of about $66.15 million.

Disclosure: none

Recommended Reading:

Tiger Global Reduces Stake in TAL Education Group (ADR) (XRS) Again

Jeff Lignelli’s Incline Global Is Betting On These Stocks: Endo Health Solutions Inc (ENDP), Tesoro Corporation (TSO) & Others

Invesco Private Capital Boosts its Stake in Brookdale Senior Living, Inc. (BKD)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!